BenzingaOctober 27, 2026 at 4:07 AM NY14 Hours Ago
Actuate Therapeutics Prices ~$11M Offering Of 30,986M Common Shares, Warrants At $0.71 Per Unit
Actuate Therapeutics, Inc. (NASDAQ: ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
